Nektar Therapeutics (NKTR) Hedge Fund Ownership (Q1 2026)

Q: Is it too late to buy Nektar Therapeutics (NKTR) following the 2026 Q2 hedge fund 13F filings?

As of today, NKTR has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), NKTR gained +4.6% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Nektar Therapeutics (NKTR)

214 + Investors. Track Smart Money conviction in NKTR. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — NKTR

Based on 215 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 3 quarters in a row

last 6Q

For 3 consecutive quarters, more hedge funds added NKTR than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

215 hedge funds hold NKTR right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +36% more funds vs a year ago

fund count last 6Q

+57 new funds entered over the past year (+36% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks. The peak was reached in just 3 quarters from the low — a sharp move.

🟢

More buyers than sellers — 64% buying

150 buying86 selling

Last quarter: 150 funds were net buyers (71 opened a brand new position + 79 added to an existing one). Only 86 were sellers (49 trimmed + 37 sold completely). A clear majority buying is a strong confirmation signal.

📈

More new buyers each quarter (+6 vs last Q)

new funds entering per quarter

Funds opening a new NKTR position: 28 → 63 → 65 → 71. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.

🔒

48% of holders stayed for 2+ years

■ 48% conviction (2yr+) ■ 18% medium ■ 33% new

104 out of 215 hedge funds have held NKTR for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

💰

Value +152% but shares only +52% — price-driven

Value

+152%

+51%

Last quarter: the total dollar value of institutional holdings rose +152%, but actual share count only changed +52%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.

📈

Growing discovery — still being found

32 → 28 → 63 → 65 → 71 new funds/Q

New funds entering each quarter: 28 → 63 → 65 → 71. A growing number of institutions are discovering NKTR each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.

🏛️

Veteran-anchored — 60% veterans vs 35% newcomers

■ 60% veterans ■ 6% 1-2yr ■ 35% new

Entry-cohort mix of 226 holders: 135 (60%) are 2+ year veterans, 13 entered 1–2 years ago, and 78 (35%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.

✅

Strong quality — 37% AUM from major funds

37% from top-100 AUM funds

35 of 214 holders rank in the top 100 by AUM, accounting for 37% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

4.7

out of 10

Moderate Exit Risk

Exit risk score 4.7/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	214	180	18.89%
13F Shares	28M	19M	51.71%
Total Value	$1.98B	$784M	152.2%
New Positions	71	65	+6
Increased Positions	74	52	+22
Closed Positions	37	34	+3
Reduced Positions	49	43	+6
Total Calls	7	8	-12.5%
Total Puts	5	6	-16.67%
PUT/CALL Ratio	0.71	0.75	Neutral

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

214

180

18.89%

13F Shares

28M

19M

51.71%

Total Value

$1.98B

$784M

152.2%

New Positions

Increased Positions

+22

Closed Positions

Reduced Positions

Total Calls

-12.5%

Total Puts

-16.67%

PUT/CALL Ratio

0.71

0.75

Neutral

Institutional Holders (2026 Q2)

214 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in NKTR. Verified SEC 13F-HR filings.

QUARTER:

2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 NKTR holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	22nw, LP	18.75%	281,115	$19.6M
2	Prosight Management, LP	9.74%	810,000	$56.5M
3	Creek Drive Management Group LLC	8.24%	243,000	$17.0M
4	APEIRON CAPITAL Ltd	4.77%	106,431	$7.4M
5	Two Seas Capital LP	4.28%	3,092,234	$215.9M
6	Bvf Inc/Il	4.27%	2,391,075	$166.9M
7	DAFNA Capital Management LLC	4.24%	318,380	$22.2M
8	Act Capital Management, LLC	4.07%	89,300	$6.2M
9	Stonepine Capital Management, LLC	3.94%	120,654	$8.4M
10	Birchview Capital, LP	2.64%	81,000	$5.7M
11	Great Point Partners LLC	2.31%	175,000	$12.2M
12	Sofinnova Investments, Inc.	1.70%	471,763	$32.9M
13	Vestal Point Capital, LP	1.63%	1,000,000	$69.8M
14	Bronte Capital Management Pty Ltd.	1.49%	198,434	$13.9M
15	KVP Capital Advisors, LP	1.38%	26,900	$1.9M
16	Ishara Investments LP	1.37%	26,650	$1.9M
17	Braidwell LP	1.22%	473,617	$33.1M
18	Exome Asset Management LLC	0.97%	22,417	$1.6M
19	Tetragon Partners GP Ltd	0.96%	86,996	$6.1M
20	Rhenman & Partners Asset Management AB	0.93%	141,250	$9.9M
21	Iridian Asset Management LLC/Ct	0.93%	38,802	$2.7M
22	Moody Aldrich Partners LLC	0.80%	64,135	$4.5M
23	ADAR1 Capital Management, LLC	0.78%	244,184	$17.0M
24	Seven Grand Managers, LLC	0.67%	240,000	$16.8M
25	Emerald Advisers, LLC	0.64%	390,158	$27.2M

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Nektar Therapeutics (NKTR)

What does the Smart Money Trend signal show for NKTR?

Buying streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds added NKTR than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for NKTR?

More buyers than sellers — 64% buying: Last quarter: 150 funds were net buyers (71 opened a brand new position + 79 added to an existing one). Only 86 were sellers (49 trimmed + 37 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for NKTR holders?

Strong quality — 37% AUM from major funds: 35 of 214 holders rank in the top 100 by AUM, accounting for 37% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held NKTR?

48% of holders stayed for 2+ years: 104 out of 215 hedge funds have held NKTR for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Nektar Therapeutics (NKTR) following the 2026 Q2 hedge fund 13F filings?

As of today, NKTR has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), NKTR has gained +4.6% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Nektar Therapeutics (NKTR)

Smart Money Signals — NKTR

Buying streak — 3 quarters in a row

At the ownership peak (100% of max)

Fast accumulation — +36% more funds vs a year ago

More buyers than sellers — 64% buying

More new buyers each quarter (+6 vs last Q)

48% of holders stayed for 2+ years

Value +152% but shares only +52% — price-driven

Growing discovery — still being found

Veteran-anchored — 60% veterans vs 35% newcomers

Strong quality — 37% AUM from major funds

Institutional Sentiment Summary — NKTR

Hedge Fund Ownership: NKTR

Market Analysis: NKTR

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: NKTR

Is It Too Late to Buy Nektar Therapeutics (NKTR) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: NKTR

Statistics: NKTR

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Nektar Therapeutics (NKTR)

Welcome to 13Foresight!